RETRACTED ARTICLE: Effects of uric acid on endothelial dysfunction in early chronic kidney disease and its mechanisms
Tóm tắt
An increase in serum uric acid (UA) occurs during the early and middle stages of chronic kidney disease (CKD) and aggravates the deterioration of kidney function. This study aims to explore the relation between UA and endothelial dysfunction in early CKD and its mechanisms in a murine model. The experimental animals were randomly divided into three groups (n = 10): sham-operation group (control group), right nephrectomy only group (CKD group) and right nephrectomy with oxonic potassium group (CKD with hyperuricemia group). Furthermore, we analyzed the relation between UA and endothelial dysfunction indices in early CKD as well as its mechanisms. Linear regression analysis showed that the level of serum UA had a significant positive correlation with serum endothelin-1 and the percentage of collagen I positive area, but a negative correlation with serum nitric oxide (NO) and NO/endothelin-1 ratio. In addition, the level of serum UA had significant positive correlations with serum malonaldehyde, serum C-reactive protein, serum oxidatively-modified low-density lipoprotein and serum low-density lipoprotein, but a negative correlation with serum superoxide dismutase. Endothelial dysfunction in the CKD group was significant and had a positive correlation with the level of serum UA. Endothelial dysfunction in early CKD with hyperuricemia is perhaps related to oxidative stress, micro-inflammation and lipid oxidation.
Tài liệu tham khảo
Gertler MM, Garn SM, Levine SA: Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951, 34: 1421–1431.
Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, Mancini M, Trevisan M: Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994, 8: 677–681.
Freedman DS, Williamson DF, Gunter EW, Byers T: Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I epidemiologic follow-up study. Am J Epidemiol 1995, 141: 637–644.
Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U: Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort: World Health Organization monitoring trends and determinants in cardiovascular diseases. Epidemiology 1999, 10: 391–397. 10.1097/00001648-199907000-00009
Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004, 164: 1546–1551. 10.1001/archinte.164.14.1546
Hajhosseiny R, Khavandi K, Goldsmith DJ: Cardiovascular disease in chronic kidney disease: untying the Gordian knot. Int J Clin Pract 2013, 67: 14–31. 10.1111/j.1742-1241.2012.02954.x
Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32: S112-S119. 10.1053/ajkd.1998.v32.pm9820470
Ohno I: Relationship between hyperuricemia and chronic kidney disease. Nucleosides Nucleotides Nucleic Acids 2011, 30: 1039–1044. 10.1080/15257770.2011.611484
Loomans CJ, De Koning EJ, Staal FJ, Rabelink TJ, Zonneveld AJ: Endothelial progenitor cell dysfunction in type 1 diabetes: another consequence of oxidative stress? Antioxid Redox Signal 2005, 7: 1468–1475. 10.1089/ars.2005.7.1468
Reinhart K, Bayer O, Brunkhorst F, Meisner M: Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002, 30: S302-S312. 10.1097/00003246-200205001-00021
Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD: Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006, 8: 79–88. 10.1593/neo.05592
Drexler H, Hornig B: Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999, 31: 51–60. 10.1006/jmcc.1998.0843
Thorin E, Webb DJ: Endothelium-derived endothelin-1. Pflugers Arch 2010, 459: 951–958. 10.1007/s00424-009-0763-y
Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M: Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 2011, 18: 1018–1028. 10.5551/jat.9084
Liao MT, Sung CC, Hung KC, Wu CC, Lo L, Lu KC: Insulin resistance in patients with chronic kidney disease. J Biomed Biotechnol 2012, 2012: 691369.
Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002, 13: 745–753.
Fridovich I: The competitive inhibition of uricase by oxonate and by related derivatives of S-triazines. J Biol Chem 1965, 240: 2491–2494.
Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002, 282: F991-F997. 10.1152/ajprenal.00283.2001
Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, Sung J, Jeon ES, Oh HY, Kim DK: Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 2004, 24: 1246–1252. 10.1161/01.ATV.0000133488.56221.4a
Edwards NL: The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol 2009, 21: 132–137. 10.1097/BOR.0b013e3283257b96
Filiopoulos V, Hadjiyannakos D, Vlassopoulos D: New insights into uric acid effects on the progression and prognosis of chronic kidney disease. Ren Fail 2012, 34: 510–520. 10.3109/0886022X.2011.653753
Jalal DI, Chonchol M, Chen W, Targher G: Uric acid as a target of therapy in CKD. Am J Kidney Dis 2013, 61(1):134–146. 10.1053/j.ajkd.2012.07.021
Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, Henderson GN: Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 2008, 27: 967–978. 10.1080/15257770802257952
Zharikov S, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER, Patel J: Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 2008, 295: C1183-C1190. 10.1152/ajpcell.00075.2008
Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288: 373–376. 10.1038/288373a0
Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B: Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001, 12: 2747–2752.
Fenster BE, Tsao PS, Rockson SG: Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J 2003, 146: 218–226. 10.1016/S0002-8703(02)94796-4
Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R: Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002, 39: 135–141. 10.1161/hy0102.100540
Kundhal K, Lok CE: Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin Pract 2005, 101: c47-c52. 10.1159/000086221
Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001, 59: 407–414. 10.1046/j.1523-1755.2001.059002407.x
Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ: C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005, 68: 766–772.
Majumdar A, Wheeler DC: Lipid abnormalities in renal disease. J R Soc Med 2000, 93: 178–182.